Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ)
002399.SZ Stock Price Chart
Explore Shenzhen Hepalink Pharmaceutical Group Co., Ltd. interactive price chart. Choose custom timeframes to analyze 002399.SZ price movements and trends.
002399.SZ Company Profile
Discover essential business fundamentals and corporate details for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
6 May 2010
Employees
1.93K
Website
https://www.hepalink.comCEO
Li Li
Description
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.
002399.SZ Financial Timeline
Browse a chronological timeline of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Dividend declared on 7 Jul 2025
A dividend of ¥0.25 per share was announced, adjusted to ¥0.25. The dividend was paid on 7 Jul 2025.
Earnings released on 24 Apr 2025
EPS came in at ¥0.11 surpassing the estimated ¥0.09 by +18.56%, while revenue for the quarter reached ¥1.39B , beating expectations by +8.97%.
Earnings released on 28 Mar 2025
EPS came in at -¥0.09 surpassing the estimated -¥0.11 by +17.36%, while revenue for the quarter reached ¥1.21B , beating expectations by +5.35%.
Earnings released on 30 Oct 2024
EPS came in at ¥0.08 surpassing the estimated ¥0.07 by +13.36%, while revenue for the quarter reached ¥1.23B , missing expectations by -3.46%.
Earnings released on 30 Aug 2024
EPS came in at ¥0.35 surpassing the estimated ¥0.31 by +11.84%, while revenue for the quarter reached ¥1.46B , missing expectations by -15.97%.
Earnings released on 29 Apr 2024
EPS came in at ¥0.11 , while revenue for the quarter reached ¥1.37B .
Earnings released on 29 Mar 2024
EPS came in at -¥0.63 falling short of the estimated ¥0.04 by -1.68K%, while revenue for the quarter reached ¥1.37B , missing expectations by -8.26%.
Earnings released on 30 Oct 2023
EPS came in at ¥0.01 falling short of the estimated ¥0.07 by -80.70%, while revenue for the quarter reached ¥1.35B , missing expectations by -8.64%.
Earnings released on 30 Aug 2023
EPS came in at ¥0.04 falling short of the estimated ¥0.14 by -72.34%, while revenue for the quarter reached ¥1.41B , missing expectations by -29.71%.
Dividend declared on 18 Jul 2023
A dividend of ¥0.10 per share was announced, adjusted to ¥0.10. The dividend was paid on 18 Jul 2023.
Earnings released on 28 Apr 2023
EPS came in at ¥0.05 falling short of the estimated ¥0.09 by -49.61%, while revenue for the quarter reached ¥1.30B , missing expectations by -20.84%.
Earnings released on 29 Mar 2023
EPS came in at ¥0.05 surpassing the estimated ¥0.02 by +150.00%, while revenue for the quarter reached ¥1.76B , missing expectations by -1.26%.
Earnings released on 28 Oct 2022
EPS came in at ¥0.10 falling short of the estimated ¥0.18 by -44.44%, while revenue for the quarter reached ¥1.64B , missing expectations by -11.76%.
Earnings released on 29 Aug 2022
EPS came in at ¥0.19 surpassing the estimated ¥0.14 by +35.71%, while revenue for the quarter reached ¥1.85B , missing expectations by -2.62%.
Dividend declared on 28 Jul 2022
A dividend of ¥0.04 per share was announced, adjusted to ¥0.04. The dividend was paid on 28 Jul 2022.
Earnings released on 29 Apr 2022
EPS came in at ¥0.16 surpassing the estimated ¥0.12 by +33.33%, while revenue for the quarter reached ¥1.73B , beating expectations by +15.08%.
Earnings released on 31 Mar 2022
EPS came in at -¥0.15 falling short of the estimated -¥0.07 by -114.29%, while revenue for the quarter reached ¥1.91B , beating expectations by +17.92%.
Earnings released on 28 Oct 2021
EPS came in at ¥0.08 , while revenue for the quarter reached ¥1.52B .
Earnings released on 27 Aug 2021
EPS came in at ¥0.13 , while revenue for the quarter reached ¥1.85B .
Dividend declared on 6 Jul 2021
A dividend of ¥0.15 per share was announced, adjusted to ¥0.15. The dividend was paid on 6 Jul 2021.
Earnings released on 29 Apr 2021
EPS came in at ¥0.10 , while revenue for the quarter reached ¥1.27B .
Earnings released on 30 Mar 2021
EPS came in at ¥0.21 , while revenue for the quarter reached ¥1.79B .
Earnings released on 29 Oct 2020
EPS came in at ¥0.09 falling short of the estimated ¥0.12 by -25.00%, while revenue for the quarter reached ¥883.28M .
002399.SZ Stock Performance
Access detailed 002399.SZ performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.